

1 **Efficacy and Safety of neoadjuvant stereotactic body radiotherapy plus adebrelimab and**
2 **chemotherapy for triple-negative breast cancer: A pilot study**

3

4 **Authors:** Guanglei Chen^{1,2,3†}, Xi Gu^{1,2,3†}, Xu Zhang^{1†}, Xiaopeng Yu^{1†}, Yu Zhang^{1,4}, Jinqi Xue^{1,2,3},
5 Ailin Li¹, Yi Zhao¹, Guijin He¹, Meiyue Tang¹, Fei Xing¹, Jianqiao Yin¹, Xiaobo Bian¹, Ye Han¹,
6 Shuo Cao¹, Chao Liu^{1,2,3}, Xiaofan Jiang^{1,2,3}, Keliang Zhang⁵, Yan Xia⁶, Huajun Li⁶, Nan Niu^{1,2,3},
7 Caigang Liu^{1,2,3*}

8

9 **Author Affiliations:**

10 ¹ Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China;

11 ² Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical
12 University, Shenyang, China;

13 ³ Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province,
14 Shenyang, China.;

15 ⁴ Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University,
16 Yantai, China;

17 ⁵ Liaoning Center for Drug Evaluation and Inspection, Shenyang, China;

18 ⁶ Jiangsu Hengrui Pharmaceuticals, Shanghai, China.

19

20 **Correspondence to**

21 Caigang Liu, Department of Oncology, Shengjing Hospital of China Medical University,
22 Shenyang 110004, China.

23 E-mail: liucg@sj-hospital.org

24

25 **Abstract**

26 **Background:** Emerging data have supported the immunostimulatory role of radiotherapy, which
27 could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but
28 suboptimal efficacy of ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed
29 a pilot study to explore the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT)
30 plus adbrelimab and chemotherapy in TNBC patients.

31 **Methods:** Treatment-naïve TNBC patients received two cycles of intravenous adbrelimab
32 (20mg/kg, every 3 weeks), and SBRT (24Gy/3f, every other day) started at the second cycle, then
33 followed by six cycles of adbrelimab plus nab-paclitaxel (125 mg/m² on days 1 and 8) and
34 carboplatin (area under the curve 6 mg/mL per min on day 1) every 3 weeks. The surgery was
35 performed within 3-5 weeks after the end of neoadjuvant therapy. Primary endpoint was
36 pathological complete response (pCR, ypT0/is ypN0). Secondary endpoints included objective
37 response rate (ORR), residual cancer burden (RCB) 0-I and safety.

38 **Results:** 13 patients were enrolled and received at least one dose of therapy. 10 (76.9%) patients
39 completed SBRT and were included in efficacy analysis. 90% (9/10) of patients achieved pCR, both
40 RCB 0-I and ORR reached 100% with 3 patients achieved complete remission. Adverse events (AEs)
41 of all-grade and grade 3-4 occurred in 92.3% and 53.8%, respectively. 1 (7.7%) patient had
42 treatment-related serious AEs. No radiation-related dermatitis or death occurred.

43 **Conclusions:** Adding SBRT to adbrelimab and neoadjuvant chemotherapy led to a substantial
44 proportion of pCR with acceptable toxicities, supporting further exploration of this combination in
45 TNBC patients.

46 **Funding:** This research did not receive any specific grant from funding agencies in the public,

47 commercial, or not-for-profit sectors.

48 **Clinical trial number:** NCT05132790.

49

50 **Introduction**

51 Triple-negative breast cancer (TNBC), defined as estrogen receptor, progesterone receptor and
52 human epidermal growth factor receptor 2 (HER2) negative, accounts for approximately 10-20% of
53 all breast cancers(Costa et al., 2017). Characterized by higher tumor mutation burden and more
54 intensive tumor-infiltrating lymphocytes (TILs) in tumor microenvironment (TME)(Loi et al., 2019),
55 TNBC is more sensitive to immune checkpoint inhibitors (ICIs) than any other subtypes(Keenan &
56 Tolaney, 2020). Nowadays, the combination with pembrolizumab (a PD-1 blockade) and standard
57 chemotherapy is recommended for TNBC patients with stage II-III according to National
58 Comprehensive Cancer Network (NCCN) guidelines(Gradishar et al., 2022). However, there is still
59 around 40% of TNBC patients cannot achieve a pathological complete response (pCR) according
60 to KEYNOTE-522 (Schmid et al., 2020) and IMpassion031 (Mittendorf et al., 2020) trials, which
61 calls for more promising strategies.

62 Radiotherapy (RT) is the most critical locoregional treatment in solid malignancies and
63 approximately half of patients may receive RT during the entire treatment period (Atun et al., 2015;
64 Citrin, 2017). Stereotactic body radiotherapy (SBRT), a novel technique with higher doses of
65 radiation delivery to the tumor lesion in a smaller number of fractions, can shorten treatment
66 duration and reduce exposure to the surrounding tissues (Chen et al., 2020). SBRT has already
67 been widely applied to advanced breast cancer as salvage treatment targeting to osseous and brain
68 metastasis or other oligometastatic sites (Nicosia et al., 2022; Viani et al., 2021). Preoperative SBRT
69 may be advantageous for downstaging the tumor to enable breast conservation and improving pCR
70 rate (Piras et al., 2023), with multiple trials investigating neoadjuvant SBRT in various malignancies

71 (Holyoake et al., 2021; Kishi et al., 2020; Liu et al., 2022; Novikov et al., 2021) are currently
72 ongoing. In addition, preclinical evidence suggested that SBRT has immunomodulatory properties
73 by inducing cancer cells necrosis and releasing neoantigens to boost neoantigen-specific immune
74 response and upregulate the expression of PD-L1 on tumor cells (Deng et al., 2014; Han et al., 2022;
75 Park et al., 2015). Given these, it would be promising to combine SBRT with ICIs and chemotherapy
76 under the neoadjuvant setting.

77 Therefore, we conducted a prospective pilot study to determine the efficacy and safety of
78 neoadjuvant SBRT in combination with adebrelimab (SHR-1316), a potent selective PD-L1
79 inhibitor, plus nab-paclitaxel and carboplatin in patients with newly-diagnosed early or locally
80 advanced TNBC, to validate the feasibility of this novel regimen in neoadjuvant treatment of TNBC.

81

82 **Methods**

83 **Patients**

84 Previously untreated patients aged between 18 and 75 years, with histologically confirmed invasive
85 triple-negative breast cancer (defined as negative estrogen receptor, progesterone receptor and
86 HER2 status by American Society of Clinical Oncology/College of American Pathologists
87 guidelines) and pathological tumor size ≥ 2.0 cm in MRI assessment, were eligible for enrollment.

88 Other inclusion criteria included Eastern Cooperative Oncology Group performance score of 0-1,
89 adequate marrow, hepatic, renal and cardiac function.

90 Key exclusion criteria included bilateral, inflammatory or occult breast cancer; active or a history
91 of autoimmune disease; use of glucocorticoids or other immunosuppressive therapy within 2 weeks

92 before the first study dose; a history of interstitial pneumonia; active tuberculosis; pregnancy,
93 lactation, and refusal to use contraception.

94

95 **Study design and treatment**

96 This single-arm, prospective study was approved by the Institutional Review Board of Shengjing
97 Hospital, China Medical University and performed in accordance with the Declaration of Helsinki
98 and Good Clinical Practice. Written informed consent was obtained from each patient. This study
99 was reported following the Strengthening the Reporting of Observational Studies in Epidemiology
100 (STROBE) reporting guidelines.

101 All patients intravenously received 8 cycles of adrebrimab (20 mg/kg every 3 weeks). SBRT
102 (24Gy/3f) targeted to breast lesion started at the second cycle every other day, and 6 cycles of nab-
103 paclitaxel (125 mg/m² on days 1 and 8) and carboplatin (area under the curve 6 mg/mL per min on
104 day 1) was given every 3 weeks since the third cycle.

105 Patients who completed or discontinued the neoadjuvant treatment could receive surgery. If
106 disease progressed during the neoadjuvant phase, the patient would either proceed to surgery or
107 receive alternative neoadjuvant therapy. Surgery was performed 3-5 weeks after the last dose of
108 neoadjuvant therapy. Recommended surgery and adjuvant therapy were administered as per local
109 guidelines or institutional standards.

110

111 **Outcomes**

112 The primary endpoint was pCR rate in the breast and axillary lymph nodes (ypT0/is ypN0).

113 Secondary endpoints included ORR before surgery (defined as the proportion of patients with
114 complete or partial response according to the Response Evaluation Criteria in Solid Tumors
115 [RECIST] version 1.1), the proportion of residual cancer burden (RCB) 0-I, and safety according to
116 the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

117

118 **Statistical analysis**

119 Efficacy was assessed in the modified intention-to-treat population, which included patients who
120 had undergone radiotherapy. Safety was evaluated in all recruited patients who received at least one
121 dose of study drug. All statistical analyses were conducted using SAS 9.4 (North Carolina, USA).
122 Continuous data are presented as mean and standard deviation (SD), or mean and 95% confidence
123 interval (CI). Categorical data are expressed as frequency and percentage. The 95% CIs of
124 pathological complete response rate, proportion of patients with RCB 0-I, and ORR were estimated
125 using the Clopper-Pearson method.

126

127 **Results**

128 **Patient characteristics**

129 Between December 2021 and January 2023, 13 patients were enrolled in the trial (*Figure 1*). The
130 baseline characteristics are shown in *Table 1*. The median age was 51 years (range 31-68) and the
131 median tumor size was 33mm (range, 22-72). Lymph node involvement was seen in 53.8% (7/13)
132 patients and 46.2% (6/13) patients had stage III breast cancer at baseline.

133

134 **Outcomes**

135 Among the 13 treated patients, 2 (15.4%) were excluded after the first dose of adbrelimab due to
136 protocol deviation and 1 (7.7%) discontinued after the second dose of adbrelimab due to adverse
137 event, thus only 10 (76.9%) who underwent neoadjuvant SBRT and surgery (the modified intention-
138 to-treat population) were available for efficacy evaluation (**Figure 1**). 9 of the ten efficacy-evaluable
139 patients (90%, 95% CI 55.5%-99.8%) achieved pCR in the breast and axillary lymph nodes, and the
140 rates of RCB 0-I was 100% (95% CI 67.9%-100.0%). The radiologic ORR was 100% (95% CI
141 67.9%-100.0%, **Table 2 and Figure 2**) with 3 patients achieved complete radiographic response. 4
142 patients with positive lymph node at baseline had nodal downstaging to N0 after neoadjuvant
143 treatment.

144

145 **Safety**

146 AEs were reported in all 13 patients (**Table 3**). The incidence of any grade AEs was 92.4%. The
147 grade 3 or higher treatment-related adverse events occurred in 53.9% of the patients, including
148 neutropenia (30.8%), anemia (7.7%), leukopenia (7.7%), thrombocytopenia (7.7%), creatine
149 phosphokinase elevation (7.7%) and diarrhea (7.7%). Immune-related adverse events of any grade
150 occurred in 23.1% of the patients with 1 (7.7%) patient experienced serious adverse events due to
151 immune-mediated myositis. 2 patients required a dose reduction of carboplatin due to AEs but
152 ultimately complete the prescribed treatment. There were no therapy-related death and no radiation-
153 related dermatitis and skin hyperpigmentation.

154

155 **Discussion**

156 This pioneering study reported the efficacy and safety of neoadjuvant SBRT in combination with
157 adbreliab, nab-paclitaxel and carboplatin in TNBC patients. This new therapeutic regimen
158 achieved promising anti-tumor activity with pCR rate of 90%, and the RCB 0-I and ORR rate of
159 100%, respectively. More importantly, this combinatory therapeutic strategy was well tolerated in
160 this population.

161 For TNBC patients who are candidates for preoperative therapy, neoadjuvant chemotherapy
162 combined with ICIs has already achieved pCR rate of 58-64.8% in KEYNOTE-522(Schmid et al.,
163 2020) and IMpassion031 study (Mittendorf et al., 2020). In our study, the addition of SBRT to
164 adbreliab and standard neoadjuvant chemotherapy achieved a significantly higher percentage of
165 pCR (90%). Since the dose of SBRT at 24Gy in 3 fractions (bioequivalent dose [BED] = 43.2Gy)
166 was lower than conventional preoperative radiotherapy dose (45-50Gy/23-25 fractions) (Ahmed et
167 al., 2021), we thought that SBRT (24Gy/3f) alone could rarely achieve pCR. We speculated that the
168 SBRT (24Gy/3f) may exert synergy with immunochemotherapy, and not just local tumor
169 eradication effects.

170 Recently, SBRT has been preclinically identified as exerting immunomodulatory effects and
171 synergizing anticancer immune responses combined with ICIs (Deng et al., 2014; Park et al., 2015).
172 Pilonis et al (Pilonis et al., 2020) discovered that SBRT (two doses of 12 Gy) improved the
173 therapeutic effects of PD-1 in a triple-negative breast cancer murine model, and this effect was
174 enhanced by the addition of chemotherapy. TONIC trial demonstrated that SBRT (24Gy/3f)
175 combined with nivolumab can increase the proportion of patients free of progression at 24 weeks

176 than nivolumab alone (17% vs 8%) (Voorwerk et al., 2019). Another small sample research has
177 indicated that preoperative SBRT (19.5-31.5Gy/3f) with neoadjuvant chemotherapy may result in
178 fair pCR rates of 36%, with the maximum response (pCR 67%) was obtained at a dose of 25.5Gy/3f
179 (Bondiau et al., 2013), as well as no increase in the incidences of early or late-term adverse events
180 (AEs) (Piras et al., 2023; Takanen et al., 2022). Together, these studies suggested SBRT may have
181 strong immunomodulatory effects, rendering a synergistic antitumor effect with immunotherapy
182 and chemotherapy.

183 Another study exploring SBRT(24Gy/3f) in combination with pembrolizumab plus
184 chemotherapy in a neoadjuvant setting for TNBC patients also achieved a promising pCR rate of
185 74% (PEARL) (McArthur et al., 2022). Noteworthy, PEARL study chose taxane-based
186 chemotherapy in which 52% of patients received platinum, while our study used nab-paclitaxel and
187 carboplatin-based regimens. It is well-established that neoadjuvant chemotherapy containing
188 platinum has shown an increase in pCR rates of approximately 15.1% in TNBC patients (Poggio et
189 al., 2018). Additionally, the IMpassion 130 (Emens et al., 2021) and IMpassion 131 (Miles et al.,
190 2021) studies have suggested that nab-paclitaxel combined with ICIs may exhibit greater efficacy
191 than paclitaxel. Thus, it is hypothesized that the selection of a chemotherapy regimen may contribute
192 to the difference of pCR rates between the PEARL and our study (74% vs 90%). Consequently, it
193 is imperative to determine the optimal neoadjuvant chemotherapy partners for ICIs in TNBC
194 population.

195 Adverse events observed in our study were generally consistent with the known safety profiles
196 of neoadjuvant therapy for TNBC patients in KEYNOTE-522 (Schmid et al., 2020) and

197 IMpassion031 (Mittendorf et al., 2020) trials. The addition of SBRT did not increase any grades or
198 grade 3 or above AEs, which were 92.3% vs 99% and 53.8% vs 57-76.8%, respectively.
199 Furthermore, consistent with the customary toxic effects observed in lung cancers with adebrelimab
200 plus carboplatin-based chemotherapy regimen (Wang et al., 2022; Yan et al., 2023), the addition of
201 SBRT neither brought new AEs nor increased the incidences of grade 3 or higher or serious AEs in
202 our population.

203 Our study had several limitations including a non-comparative preliminary trial with relatively
204 small sample size, thereby impeding the comparison of our data with historical data due to
205 insufficient statistical power. Thus, further prospective randomized clinical trial required to validate
206 these outcomes is currently at the planning stage.

207 In conclusion, the addition of SBRT to adebrelimab and neoadjuvant platinum-containing therapy
208 showed the possibility of a convenient and feasible regimen for TNBC with promising efficacy and
209 acceptable toxicities. Neoadjuvant radiotherapy may enhance the response to immunochemotherapy
210 through activating tumor microenvironment. Further confirmation of these findings in large-scale
211 study is currently underway.

212

213 **Acknowledgments**

214 Jiangsu Hengrui Pharmaceuticals Co., Ltd provided the study drug adebrelimab free of charge for
215 patients enrolled in the study. We thank the patients and their families involved in this study.

216

217 **Additional information**

218 **Conflict of interest**

219 Yan Xia and Huajun Li are the employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other
220 potential conflicts of interest were reported.

221

222 **Funding**

223 This research did not receive any specific grant from funding agencies in the public, commercial,
224 or not-for-profit sectors.

225

226 **Authors' contributions**

227 G. Chen, Data curation, methodology. X. Gu, Data curation, Methodology. X. Zhang, Methodology.

228 X. Yu, Methodology. Y. Zhang: Data curation, formal analysis, methodology. J. Xue, Methodology.

229 A. Li, Conceptualization, methodology. Y. Zhao, Methodology. G. He, Methodology. M. Tang,

230 Data curation. F. Xing, Methodology. J. Yin, Methodology. X. Bian, Methodology. Y. Han,

231 Methodology. S. Cao, Methodology. C. Liu, Formal analysis, methodology. X. Jiang, Writing-

232 original draft. K. Zhang, Methodology. Y. Xia, Formal analysis. H. Li, Formal analysis. N. Niu,

233 Validation, data curation, formal analysis, methodology, writing–review and editing. Caigang Liu,

234 Conceptualization, supervision, project administration, writing–review and editing.

235

236 **Author ORCIDs**

237 Caigang Liu <https://orcid.org/0000-0003-2083-235X>

238

239 **Ethics approval and consent to participate**

240 The study was approved by Institutional Review Board of Shengjing Hospital, China Medical

241 University and performed, according to the Declaration of Helsinki and Good Clinical Practice

242 guidelines. Written informed consent was obtained from each patient.

243

244 **Consent for publication**

245 All authors have read and approved the final version of this manuscript.

246

247 **Data availability statement**

248 The raw clinical and imaging data are protected due to patient privacy laws. The datasets generated

249 and/or analyzed during the current study are restricted from public access by related policy and law,

250 but available from the corresponding author upon reasonable request for 10 years; de-identified

251 clinical data and experimental data are available on request sharing, which will need the approval

252 of the Institutional Ethical Committees. De-identified data will then be transferred to the inquiring

253 investigator over secure file transfer.

254

255 **References**

- 256 Ahmed, M., Jozsa, F., & Douek, M. (2021). A systematic review of neo-adjuvant radiotherapy in the
257 treatment of breast cancer. *Ecancermedicalscience*, *15*, 1175.
258 <https://doi.org/10.3332/ecancer.2021.1175>
259
- 260 Atun, R., Jaffray, D. A., Barton, M. B., Bray, F., Baumann, M., Vikram, B., Hanna, T. P., Knaul, F. M.,
261 Lievens, Y., Lui, T. Y., Milosevic, M., O'Sullivan, B., Rodin, D. L., Rosenblatt, E., Van Dyk, J.,
262 Yap, M. L., Zubizarreta, E., & Gospodarowicz, M. (2015, Sep). Expanding global access to
263 radiotherapy. *Lancet Oncol*, *16*(10), 1153-1186. [https://doi.org/10.1016/S1470-](https://doi.org/10.1016/S1470-2045(15)00222-3)
264 [2045\(15\)00222-3](https://doi.org/10.1016/S1470-2045(15)00222-3)
265
- 266 Bondiau, P. Y., Courdi, A., Bahadoran, P., Chamorey, E., Queille-Roussel, C., Lallement, M., Birtwisle-
267 Peyrottes, I., Chapellier, C., Pacquelet-Cheli, S., & Ferrero, J. M. (2013, Apr 1). Phase 1
268 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant
269 chemotherapy for breast cancer. *Int J Radiat Oncol Biol Phys*, *85*(5), 1193-1199.
270 <https://doi.org/10.1016/j.ijrobp.2012.10.034>
271
- 272 Chen, Y., Gao, M., Huang, Z., Yu, J., & Meng, X. (2020, Jul 28). SBRT combined with PD-1/PD-L1
273 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future
274 challenges. *J Hematol Oncol*, *13*(1), 105. <https://doi.org/10.1186/s13045-020-00940-z>
275
- 276 Citrin, D. E. (2017, Sep 14). Recent Developments in Radiotherapy. *N Engl J Med*, *377*(11), 1065-
277 1075. <https://doi.org/10.1056/NEJMra1608986>
278
- 279 Costa, R., Shah, A. N., Santa-Maria, C. A., Cruz, M. R., Mahalingam, D., Carneiro, B. A., Chae, Y. K.,
280 Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017, Feb). Targeting Epidermal Growth
281 Factor Receptor in triple negative breast cancer: New discoveries and practical insights for
282 drug development. *Cancer Treat Rev*, *53*, 111-119.
283 <https://doi.org/10.1016/j.ctrv.2016.12.010>
284
- 285 Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y. X. (2014, Feb).
286 Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
287 *J Clin Invest*, *124*(2), 687-695. <https://doi.org/10.1172/JCI67313>
288
- 289 Emens, L. A., Adams, S., Barrios, C. H., Dieras, V., Iwata, H., Loi, S., Rugo, H. S., Schneeweiss, A.,
290 Winer, E. P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Patel, S., Chui, S. Y., &
291 Schmid, P. (2021, Aug). First-line atezolizumab plus nab-paclitaxel for unresectable,
292 locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall
293 survival analysis. *Ann Oncol*, *32*(8), 983-993.
294 <https://doi.org/10.1016/j.annonc.2021.05.355>
295

- 296 Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein,
297 H. J., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Hurvitz,
298 S. A., Isakoff, S. J., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., Leitch, M., Lyons, J.,
299 Mortimer, J., Patel, S. A., Pierce, L. J., Rosenberger, L. H., Rugo, H. S., Sitapati, A., Smith, K.
300 L., Smith, M. L., Soliman, H., Stringer-Reasor, E. M., Telli, M. L., Ward, J. H., Wisinski, K. B.,
301 Young, J. S., Burns, J., & Kumar, R. (2022, Jun). Breast Cancer, Version 3.2022, NCCN
302 Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 20(6), 691-722.
303 <https://doi.org/10.6004/jnccn.2022.0030>
304
- 305 Han, M. G., Wee, C. W., Kang, M. H., Kim, M. J., Jeon, S. H., & Kim, I. A. (2022, May 29). Combination
306 of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-
307 Negative Breast Cancer Model. *Cancers (Basel)*, 14(11).
308 <https://doi.org/10.3390/cancers14112692>
309
- 310 Holyoake, D. L. P., Robinson, M., Silva, M., Grose, D., McIntosh, D., Sebag-Montefiore, D.,
311 Radhakrishna, G., Mukherjee, S., & Hawkins, M. A. (2021, Feb). SPARC, a phase-I trial of
312 pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic
313 cancer. *Radiother Oncol*, 155, 278-284. <https://doi.org/10.1016/j.radonc.2020.11.007>
314
- 315 Keenan, T. E., & Tolaney, S. M. (2020, Apr). Role of Immunotherapy in Triple-Negative Breast
316 Cancer. *J Natl Compr Canc Netw*, 18(4), 479-489.
317 <https://doi.org/10.6004/jnccn.2020.7554>
318
- 319 Kishi, N., Kanayama, N., Hirata, T., Ohira, S., Wada, K., Kawaguchi, Y., Konishi, K., Nagata, S.,
320 Nakatsuka, S. I., Marubashi, S., Tomokuni, A., Wada, H., Kobayashi, S., Tomita, Y., &
321 Teshima, T. (2020, Mar 5). Preoperative Stereotactic Body Radiotherapy to Portal Vein
322 Tumour Thrombus in Hepatocellular Carcinoma: Clinical and Pathological Analysis. *Sci*
323 *Rep*, 10(1), 4105. <https://doi.org/10.1038/s41598-020-60871-0>
324
- 325 Liu, Y., Veale, C., Hablitz, D., Krontiras, H., Dalton, A., Meyers, K., Dobelbower, M., Lancaster, R.,
326 Bredel, M., Parker, C., Keene, K., Thomas, E., & Boggs, D. (2022). Feasibility and Short-
327 Term Toxicity of a Consecutively Delivered Five Fraction Stereotactic Body Radiation
328 Therapy Regimen in Early-Stage Breast Cancer Patients Receiving Partial Breast Irradiation.
329 *Front Oncol*, 12, 901312. <https://doi.org/10.3389/fonc.2022.901312>
330
- 331 Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V.,
332 Badve, S., Demaria, S., Gray, R., Munzone, E., Lemonnier, J., Sotiriou, C., Piccart, M. J.,
333 Kellokumpu-Lehtinen, P. L., Vingiani, A., Gray, K., Andre, F., Denkert, C., Salgado, R., &
334 Michiels, S. (2019, Mar 1). Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled
335 Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *J Clin Oncol*,
336 37(7), 559-569. <https://doi.org/10.1200/JCO.18.01010>
337

- 338 McArthur, H. L., Shiao, S., Karlan, S., Basho, R., Amersi, F., Burnison, M., Mirhadi, A., Chung, A.,
339 Chung, C. T., Dang, C., Richardson, H., Giuliano, A. E., Kapoor, N., Larkin, B., Godinez, H.,
340 Dunn, S. A., Khameneh, N. H., Knott, S., McAndrew, P., Mita, M., Park, D. J., Abaya, C., Chen,
341 J. H., Ly, A., Bossuyt, V., & Ho, A. (2022). Abstract PD10-01: The PEARL trial: Pre-operative
342 pembrolizumab with radiation therapy in early stage triple negative breast cancer. *Cancer*
343 *Research*, *82*(4_Supplement), PD10-01-PD10-01. [https://doi.org/10.1158/1538-](https://doi.org/10.1158/1538-7445.Sabcs21-pd10-01)
344 [7445.Sabcs21-pd10-01](https://doi.org/10.1158/1538-7445.Sabcs21-pd10-01)
345
- 346 Miles, D., Gligorov, J., Andre, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen,
347 D., Andrade, L., Semiglazov, V., Reinisch, M., Patel, S., Patre, M., Morales, L., Patel, S. L.,
348 Kaul, M., Barata, T., O'Shaughnessy, J., & investigators, I. M. (2021, Aug). Primary results
349 from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of
350 first-line paclitaxel with or without atezolizumab for unresectable locally
351 advanced/metastatic triple-negative breast cancer. *Ann Oncol*, *32*(8), 994-1004.
352 <https://doi.org/10.1016/j.annonc.2021.05.801>
353
- 354 Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata,
355 H., Telli, M. L., Ferrario, C., Punie, K., Penault-Llorca, F., Patel, S., Duc, A. N., Liste-Hermoso,
356 M., Maiya, V., Molinero, L., Chui, S. Y., & Harbeck, N. (2020, Oct 10). Neoadjuvant
357 atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based
358 chemotherapy versus placebo and chemotherapy in patients with early-stage triple-
359 negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. *Lancet*,
360 *396*(10257), 1090-1100. [https://doi.org/10.1016/S0140-6736\(20\)31953-X](https://doi.org/10.1016/S0140-6736(20)31953-X)
361
- 362 Nicosia, L., Figlia, V., Ricottone, N., Cuccia, F., Mazzola, R., Giaj-Levra, N., Ricchetti, F., Rigo, M.,
363 Jafari, F., Maria Magrini, S., Girlando, A., & Alongi, F. (2022, Aug). Stereotactic body
364 radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer
365 patients. *Clin Exp Metastasis*, *39*(4), 581-588. [https://doi.org/10.1007/s10585-022-](https://doi.org/10.1007/s10585-022-10167-6)
366 [10167-6](https://doi.org/10.1007/s10585-022-10167-6)
367
- 368 Novikov, S. N., Gafton, G. I., Ebert, M. A., Fedosova, E. A., Melnik, J. S., Zinovev, G. V., Gafton, I. G.,
369 Sinyachkin, M. S., & Kanaev, S. V. (2021, Aug). Preoperative stereotactic ablative body
370 radiotherapy with postoperative conventional irradiation of soft tissue sarcomas: Protocol
371 overview with a preliminary safety report. *Radiother Oncol*, *161*, 126-131.
372 <https://doi.org/10.1016/j.radonc.2021.05.025>
373
- 374 Park, S. S., Dong, H., Liu, X., Harrington, S. M., Krco, C. J., Grams, M. P., Mansfield, A. S., Furutani, K.
375 M., Olivier, K. R., & Kwon, E. D. (2015, Jun). PD-1 Restrains Radiotherapy-Induced
376 Abscopal Effect. *Cancer Immunol Res*, *3*(6), 610-619. [https://doi.org/10.1158/2326-](https://doi.org/10.1158/2326-6066.CIR-14-0138)
377 [6066.CIR-14-0138](https://doi.org/10.1158/2326-6066.CIR-14-0138)
378
- 379 Pilonis, K. A., Hensler, M., Daviaud, C., Kraynak, J., Fucikova, J., Galluzzi, L., Demaria, S., & Formenti,

- 380 S. C. (2020, Oct 20). Converging focal radiation and immunotherapy in a preclinical model
381 of triple negative breast cancer: contribution of VISTA blockade. *Oncoimmunology*, *9*(1),
382 1830524. <https://doi.org/10.1080/2162402X.2020.1830524>
383
- 384 Piras, A., Sanfratello, A., Boldrini, L., D'Aviero, A., Pernice, G., Sortino, G., Valerio, M. R., Gennari, R.,
385 D'Angelo, I., Marazzi, F., Angileri, T., & Daidone, A. (2023). Stereotactic Radiotherapy in
386 Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review.
387 *Oncol Res Treat*, *46*(3), 116-123. <https://doi.org/10.1159/000528640>
388
- 389 Poggio, F., Bruzzone, M., Ceppi, M., Ponde, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., &
390 Lambertini, M. (2018, Jul 1). Platinum-based neoadjuvant chemotherapy in triple-
391 negative breast cancer: a systematic review and meta-analysis. *Ann Oncol*, *29*(7), 1497-
392 1508. <https://doi.org/10.1093/annonc/mdy127>
393
- 394 Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kummel, S., Bergh, J., Denkert, C., Park, Y. H., Hui,
395 R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L.,
396 Karantza, V., Zhao, J., Aktan, G., Dent, R., O'Shaughnessy, J., & Investigators, K.-. (2020,
397 Feb 27). Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med*, *382*(9),
398 810-821. <https://doi.org/10.1056/NEJMoa1910549>
399
- 400 Takanen, S., Pinnaro, P., Farina, I., Sperati, F., Botti, C., Vici, P., Soriani, A., Marucci, L., & Sanguineti,
401 G. (2022). Stereotactic partial breast irradiation in primary breast cancer: A comprehensive
402 review of the current status and future directions. *Front Oncol*, *12*, 953810.
403 <https://doi.org/10.3389/fonc.2022.953810>
404
- 405 Viani, G. A., Gouveia, A. G., Louie, A. V., Korzeniowski, M., Pavoni, J. F., Hamamura, A. C., & Moraes,
406 F. Y. (2021, Nov). Stereotactic body radiotherapy to treat breast cancer oligometastases:
407 A systematic review with meta-analysis. *Radiother Oncol*, *164*, 245-250.
408 <https://doi.org/10.1016/j.radonc.2021.09.031>
409
- 410 Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof,
411 I., Kluin, R. J. C., Warren, S., Ong, S., Wiersma, T. G., Russell, N. S., Lalezari, F., Schouten, P.
412 C., Bakker, N. A. M., Ketelaars, S. L. C., Peters, D., Lange, C. A. H., van Werkhoven, E., van
413 Tinteren, H., Mandjes, I. A. M., Kemper, I., Onderwater, S., Chalabi, M., Wilgenhof, S.,
414 Haanen, J., Salgado, R., de Visser, K. E., Sonke, G. S., Wessels, L. F. A., Linn, S. C.,
415 Schumacher, T. N., Blank, C. U., & Kok, M. (2019, Jun). Immune induction strategies in
416 metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the
417 TONIC trial. *Nat Med*, *25*(6), 920-928. <https://doi.org/10.1038/s41591-019-0432-4>
418
- 419 Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., Yang, R., Yu,
420 G., Gong, Y., Zhao, J., Fan, Y., Liu, Q., Cao, L., Yao, Y., Liu, Y., Li, X., Wu, J., He, Z., Lu, K.,
421 Jiang, L., Hu, C., Zhao, W., Zhang, B., Shi, W., Zhang, X., Cheng, Y., & Group, C.-S. (2022,

422 Jun). Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for
423 extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised,
424 double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*, 23(6), 739-747.
425 [https://doi.org/10.1016/S1470-2045\(22\)00224-8](https://doi.org/10.1016/S1470-2045(22)00224-8)

426

427 Yan, W., Zhong, W. Z., Liu, Y. H., Chen, Q., Xing, W., Zhang, Q., Liu, L., Ge, D., Chen, K., Yang, F., Lin,
428 X., Song, L., Shi, W., & Wu, Y. L. (2023, Feb). Adebrelimab (SHR-1316) in Combination With
429 Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III
430 NSCLCs: An Open-Label, Multicenter, Phase 1b Trial. *J Thorac Oncol*, 18(2), 194-203.
431 <https://doi.org/10.1016/j.jtho.2022.09.222>

432

433

434

435

Table 1. Baseline characteristics

Characteristic	Patients (n=13)
Age (median, range)	51 (31-68)
Age Group, years	
≤ 50	6 (46.2%)
> 50	7 (53.8%)
Menopausal status	
Premenopausal	6 (46.2%)
Postmenopausal	7 (53.8%)
Tumor size	
T2	10 (76.9%)
T3	3 (23.1%)
Lymph node status	
N0	6 (46.2%)
N1	2 (15.4%)
N2	5 (38.5%)
Clinical stage	
IIA	6 (46.2%)
IIB	1 (7.7%)
IIIA	6 (46.2%)
Tumor grade	
II	6 (46.2%)
III	5 (38.5%)
Unknown	2 (15.4%)
HER2 expression	
Negative	8 (61.5%)
1+	3 (23.1%)
2+, FISH-	2 (15.4%)

436

437

Table 2. Pathological and clinical response

Variable	Patients (n=10)
Total pathological complete response	9 (90%)
Residual cancer burden score	
0	9 (90%)
I	1 (10%)
II	0
III	0
Radiological response	
Complete response	3 (30%)
Partial response	7 (70%)
Stable disease	0
Objective response rate	10 (100%)

438

439

440

Table 3. Treatment-related adverse events

	Patients (n=13)		
	Grade 1 or 2	Grade 3	Grade 4
Total	5 (38.5%)	6 (46.2%)	1 (7.7%)
Anemia	8 (61.5%)	1 (7.7%)	0
Alopecia	9 (69.2%)	0	0
Neutropenia	4 (30.8%)	3 (23.1%)	1 (7.7%)
Hyponatremia	8 (61.5%)	0	0
Nausea	8 (61.5%)	0	0
Leukopenia	6 (46.2%)	1 (7.7%)	0
Lymphopenia	7 (53.8%)	0	0
Thrombocytopenia	5 (38.5%)	1 (7.7%)	0
Elevated alanine aminotransferase level	5 (38.5%)	0	0
Elevated aspartate aminotransferase level	5 (38.5%)	0	0
Thyroid stimulating hormone decreased	5 (38.5%)	0	0
Hyperuricemia	5 (38.5%)	0	0
Vomiting	5 (38.5%)	0	0
Fatigue	4 (30.8%)	0	0
γ-glutamyl transferase increased	3 (23.1%)	0	0
Creatinine increased	3 (23.1%)	0	0
Thyroid stimulating hormone increased	3 (23.1%)	0	0
Creatine phosphokinase elevation	1 (7.7%)	1 (7.7%)	0
Hyperthyroidism	2 (15.4%)	0	0
Free thyroid hormone decreased	2 (15.4%)	0	0
Hyperglycemia	2 (15.4%)	0	0
Hypokalemia	2 (15.4%)	0	0
Rash	2 (15.4%)	0	0
Peripheral neuropathy	2 (15.4%)	0	0
Diarrhea	0	1 (7.7%)	0
Immune mediated myositis	1 (7.7%)	0	0
Ventricular extrasystole	1 (7.7%)	0	0
Free thyroid hormone increased	1 (7.7%)	0	0
Hypothyroidism	1 (7.7%)	0	0
Troponin I elevated	1 (7.7%)	0	0
Proteinuria	1 (7.7%)	0	0
Constipation	1 (7.7%)	0	0

441

442

443 **FIGURE LEGENDS**

444 **Figure 1** Flowchart of the trial. SBRT, stereotactic body radiotherapy.

445 **Figure 2** Swimming plot which demonstrate the pCR, RCB and radiological response profile of ten
446 modified intention-to-treat population who received radiotherapy and undergone surgery. Each
447 round dot or column indicates a patient. Colors indicate different clinical stage. ID, identity; pCR,
448 pathological complete response; RCB, residual cancer burden.

449

Figure 1




Figure 2

